High prevalence of respiratory infections due to RSV is a major factor driving growth of the respiratory syncytial virus diagnostics market. According to a report by the Lancet, 2017, around 33·1 million episodes of RSV induced acute lower respiratory infections that resulted in around 3·2 million hospitalizations and around 59,600 in-hospital deaths in children younger than 5 years of age, worldwide, in 2015. Moreover, the report stated that the overall RSV- acute lower respiratory infections- related mortality was around 118200 in 2015.

Get a Request Sample of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2038

Furthermore, high prevalence of several chronic conditions such as pneumonia and other respiratory tract infections due to RSV is a major factor contributing to growth of the market over the forecast period. For instance, according to a report by World Health Organization (WHO), May 2018, chronic obstructive pulmonary disease (COPD) and lower respiratory tract infection are amongst top five chronic diseases with highest mortality rate, worldwide. The report stated that around 3 million each deaths were registered due to COPD and lower respiratory tract infection in 2016, worldwide.

Key players operating in the respiratory syncytial virus diagnostics market include, F. Hoffmann La-Roche AG , Becton, Dickinson and Company, Novartis AG, Abbott Laboratories, Ortho Clinical Diagnostics, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., BioMerieux, DiaSorin SPA, Millipore-sigma, Quidel Corporation, Alere Inc., Coris BioConcept, Fast-track Diagnostics, and Quest Diagnostics.

Request for Customization of Research Report: https://www.coherentmarketinsights.com/insight/request-customization/2038

In 2016, BD (Becton, Dickinson and Company) launched its wireless rapid diagnostic system named—Veritor Plus— for detection of respiratory syncytial virus (RSV), influenza A and B, and group A strep—with new traceability and secure patient-health record documentation features and functionality. In October 2017, Abbott Laboratories completed acquisition of the Alere, Inc. which provides RSV diagnostic system such as ALERE i RSV.

Furthermore, children in this region often do not receive adequate vaccination, which leads to frequent infection incidences from variety of diseases including RSV. According to World Health Organization (WHO) 2018, worldwide, around 86% of infants are vaccinated against 26 diseases. However, around 19.5 million children remain unvaccinated that leads to around 2-3 million deaths, annually, of which around 90% belong to low and middle income countries.

Inquire about Discount on this Report @ https://www.coherentmarketinsights.com/insight/request-discount/2038

WHO is running the pilot projects of vaccination in countries of developing regions such Latin America, Africa, and Asia Pacific to achieve100% detection of the RSV infections amongst infants, neonates and children under five years of age.This is expected to reduce the mortality rate and hospitalization from RSV associated acute lower respiratory infections (ALRI). It would also establish RSV diagnostic centers over the forecast period in these regions.